The study covered in this summary was published on ResearchSquare.com as a preprint and has not yet been peer reviewed. In patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP ...
Various clinical scores are available to assess the outcome of chronic inflammatory demyelinating polyneuropathy (CIDP), but these existing scales have some major limitations. A novel, simple scoring ...
Chinese scientists reveal the feasibility, tolerability, and efficacy of BCMA-CD19 bispecific CAR T-cells for treating chronic inflammatory demyelinating polyneuropathy (CIDP) and highlight the ...
Chronic inflammatory demyelinating polyneuropathy (CIDP) may be a rare disease, but it is one of the most common forms of neuropathy and the most common form of chronic autoimmune neuropathy. Roughly ...
Chronic inflammatory demyelinating polyneuropathy, or CIDP, is a rare autoimmune disease that can cause severe numbness, weakness and disability. In a recent interview hosted by Sanofi, Dr. Jeffrey ...
The GBS\|CIDP Foundation International is thrilled to announce the publication of shared key terms to describe the management o ...
Treatment for chronic inflammatory demyelinating polyneuropathy (CIDP), a chronic autoimmune condition that affects the protective layer around your nerves, usually starts with one of three options.
Chronic inflammatory demyelinating polyneuropathy (CIDP) diagnoses are frequently missed or delayed and standard treatments -- intravenous immunoglobulin (IVIG), steroids, and plasma exchange -- are ...
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a long-term neurological disorder that targets your body’s nerves. Anyone can get CIDP, but it’s most common in older adults and more common ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results